acetyl cysteine ​​and ACETAZOLAMIDE FOR THE TREATMENT OF CHRONIC MOUNTAIN SICKNESS IN SETTLERS OF HIGHLANDS OF THE PERUVIAN ANDES

Not Applicable

• Registration Number: PER-050-12
• Lead Sponsor: Thomas H Maren Foundation,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-09
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Sex: Male
• Target Recruitment: 0

Inclusion Criteria

• MALE SUBJECT (WOMEN WILL BE EXCLUDED TO AVOID MENSTRUAL PROBLEMS)
• AGE: 18 YEARS OR MORE.
• HEMATOCRIT> 65%.
• MMC SCORE> 6 (ANNEX 1). SCORE IS 0-3 IN THE PRESENCE OF 10 FEATURES INCLUDING: HEADACHE, DIZZINESS, MENTAL WEAKNESS, MENTAL FATIGUE, Dyspnea, INSOMNIA, TINNITUS, ANOREXIA, CYANOSIS, AND conjunctival hyperemia (1).

Exclusion Criteria

• PREVIOUS HISTORY OF ALLERGY / ADVERSE REACTION TO ACTZ OR NAC
• SMOKING CIGARETTES OVER 5 / DAY.
• PHLEBOTOMY IN THREE MONTHS PRIOR TO THE STUDY.
• SERUM POTASSIUM < 3.5 MEQ / L
• SERUM SODIUM <128 MEQ / L
• SCORE MMC > 15
• PULMONARY DISEASE, ASTHMA INCLUDING, WITH THE REQUIREMENT OF USE OF OXYGEN.
• Cirrhosis
• ADRENAL FAILURE
• Aspirin CONSUMPTION> 1 GR / DAY
• CONTRAINDICATIONS FOR ARTERIAL BLOOD SAMPLING FROM RADIAL ARTERY.

Study & Design

• Study Type: Interventional
• Study Design: Not specified